Dr. Odumosu brings 10 years of experience in corporate pharmaceutical business development, operations and strategic alliance management to his role as Ilera Healthcare’s Chief Scientific Officer/EVP Pharmaceutical Division. His background in biochemistry and healthcare entrepreneurship gives him unique qualifications for this role. Dr. Odumosu played a critical role in Iroko Pharmaceutical’s post-clinical development of Zorvolex Tivorbex and Vivlodex through FDA approvals and successful US market commercialization. He also managed the execution of the business development gate processes for the expansion of Iroko’s Solumatrix franchise products through ex-US licensing agreement negotiations. He received a PhD in Biochemistry and a Master’s in Public Health-Epidemiology and Biostatistics from the Loma Linda University School of Medicine and School of Public Health in Loma Linda, California; and a BS in Biology from Calvin College in Grand Rapids, Michigan. Dr. Odumosu is a World Bank Institute Certified public health professional with global healthcare translational/clinical/epidemiological research and data management experience.